Veru Inc. VERU
Veru Inc. (Nasdaq: VERU) is a cardio-renal-metabolic drug developer. Its lead program, enobosarm, is in Phase 2 for Preservation of muscle during GLP-1 RA-induced weight loss in older patients with obesity. Its next catalyst on record is sabizabulin: Veru plans a Phase 2b clinical study of sabizabulin in metastatic pancreatic cancer resistant to daraxonrasib, with preIND FDA meeting expected in Q4 2026. (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: sabizabulin — Veru plans a Phase 2b clinical study of sabizabulin in metastatic pancreatic cancer resistant to daraxonrasib, with preIND FDA meeting expected in Q4 2026. (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| enobosarm (oral SARM) - Phase 2b PLATEAU | Obesity (add-on to GLP-1 RA) | small molecule | Phase 2 |
| sabizabulin | Inflammation in atherosclerotic cardiovascular disease (hs-CRP) | small molecule | Pre-clinical |
Recent results and decisions
- Sep 8, 2026n/a New preclinical data: sabizabulin retained potent activity in daraxonrasib-resistant pancreatic cells (IC50 18.2 nM, resistance index 0.25); company will advance to a Phase 2b and drop the atherosclerosis indication.
Based on the new, positive preclinical data, and the previous preclinical and clinical sabizabulin studies, the Company will advance sabizabulin into a planned Phase 2 clinical trial for metastatic KRAS-driven pancreatic cancer progression that has become resistant to the recent FDA approved daraxon
Filing - Sep 8, 2026completed enrollment Veru completed full enrollment of 239 patients in the Phase 2b PLATEAU clinical trial of enobosarm plus semaglutide for obesity.
During the past quarter, the Company exceeded its Phase 2b PLATEAU clinical trial targeted full enrollment of 200 patients by enrolling 239 patients.
Filing - Sep 8, 2026discontinued Veru will no longer explore sabizabulin for the treatment of chronic inflammation related to atherosclerotic cardiovascular disease.
Consequently, we will no longer be exploring sabizabulin for the treatment of chronic inflammation related to atherosclerotic cardiovascular disease.
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.